These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 16307164)

  • 21. Efficacy and tolerability of the combination valsartan/hydrochlorothiazide compared with amlodipine in a mild-to-moderately hypertensive Brazilian population.
    Franco RJ; Goldflus S; McQuitty M; Oigman W;
    Blood Press Suppl; 2003 Dec; 2():41-7. PubMed ID: 14761076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension.
    Calhoun DA; Glazer RD; Pettyjohn FS; Coenen PD; Zhao Y; Grosso A
    Curr Med Res Opin; 2008 Aug; 24(8):2303-11. PubMed ID: 18593517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exforge HCT.
    Med Lett Drugs Ther; 2009 Jun; 51(1314):47. PubMed ID: 19528888
    [No Abstract]   [Full Text] [Related]  

  • 24. [High dose sartan plus thiazide. Power duo in hypertension].
    MMW Fortschr Med; 2003 Feb; 145(6):60. PubMed ID: 12619369
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults.
    Pool JL; Glazer R; Weinberger M; Alvarado R; Huang J; Graff A
    Clin Ther; 2007 Jan; 29(1):61-73. PubMed ID: 17379047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of valsartan compared with valsartan/hydrochlorothiazide on plasma levels of cellular adhesion molecules: the Val-MARC trial.
    Conen D; Everett BM; Glynn RJ; Ridker PM
    Heart; 2008 Mar; 94(3):e13. PubMed ID: 17923463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pill burden in hypertensive patients treated with single-pill combination therapy--an observational study.
    Hagendorff A; Freytag S; Müller A; Klebs S
    Adv Ther; 2013 Apr; 30(4):406-19. PubMed ID: 23532555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C; Croce G; Desideri G
    Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan/HCT).
    Chrysant SG
    Expert Rev Cardiovasc Ther; 2003 Sep; 1(3):335-43. PubMed ID: 15030262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Intensive blood pressure reduction in patients with increased cardiovascular risk with high-dose combination therapy of 160 mg valsartan plus 25 mg hydrochlorothiazide. Results of the MACHT II observational study].
    Schühlen H; Abts M; Kastrati D
    Herz; 2007 Aug; 32(5):419-25. PubMed ID: 17687532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sexual activity in hypertensive men.
    Della Chiesa A; Pfiffner D; Meier B; Hess OM
    J Hum Hypertens; 2003 Aug; 17(8):515-21. PubMed ID: 12874608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
    Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
    Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial.
    White WB; Murwin D; Chrysant SG; Koval SE; Davidai G; Guthrie R
    Blood Press Monit; 2008 Feb; 13(1):21-7. PubMed ID: 18199920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing.
    Hermida RC; Ayala DE; Fontao MJ; Mojón A; Fernández JR
    Chronobiol Int; 2010 Jul; 27(6):1287-303. PubMed ID: 20653455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy.
    Weber MA; Julius S; Kjeldsen SE; Jia Y; Brunner HR; Zappe DH; Hua TA; McInnes GT; Schork A; Mancia G; Zanchetti A
    J Hypertens; 2012 Nov; 30(11):2213-22. PubMed ID: 23011525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antihypertensive therapy with CCB/ARB combination in older individuals: focus on amlodipine/valsartan combination.
    Kostis JB
    Am J Ther; 2010; 17(2):188-96. PubMed ID: 19433970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [VALUE study underscores the significance of reaching aimed blood pressure values for minimizing cardiovascular risks].
    Praxis (Bern 1994); 2004 Oct; 93(42):1748. PubMed ID: 15529964
    [No Abstract]   [Full Text] [Related]  

  • 38. Initial combination therapy with amlodipine/valsartan compared with monotherapy in the treatment of hypertension.
    Philipp T; Glazer RD; Wernsing M; Yen J
    J Am Soc Hypertens; 2011; 5(5):417-24. PubMed ID: 21592879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Re: Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination.
    Vivencio B
    Curr Med Res Opin; 2009 Sep; 25(9):2267-8; author reply 2268-9. PubMed ID: 19630488
    [No Abstract]   [Full Text] [Related]  

  • 40. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial.
    Schmieder RE; Kjeldsen SE; Julius S; McInnes GT; Zanchetti A; Hua TA;
    J Hypertens; 2008 Mar; 26(3):403-11. PubMed ID: 18300848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.